Modus Therapeutics snaps up $3.6 mln
Stockholm-based Modus Therapeutics, which focuses on treating patients with sickle cell disease, has secured $3.6 million in funding. The investors were KDev Investments, Östersjöstiftelsen and Praktikerinvest.
22 February 2017•1 min read
